Non-small Cell Lung Cancer
Conditions
Keywords
PD-L1 ;RET Fusion Lung Cancer Patients
Brief summary
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.
Detailed description
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus the PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer. We aim to enrolled 100 patients in this study, the primary endpoint was PFS.
Interventions
None listed
Sponsors
Hunan Province Tumor Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * RET Fusion Positive * First Diagnosis and Treatment * Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Exclusion criteria
* \- Patients received antitumor treatment before * Patients with contraindication of chemotherapy * Pregnant or breast feeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | may 2020- may 2021 (1 year) | Progression free survival time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | may 2020- may 2021 (1 year) | Overal response rate |
| OS | may 2020- may 2021 (1 year) | Overall survival time |
Countries
China
Contacts
Primary ContactYongchang Zhang, MD
Backup ContactNong Yang, MD
Outcome results
None listed